Pharmacokinetics and safety of pegylated recombinant human granulocyte colony-stimulating factor in children with acute leukaemia.

Xi-Ting LiuYan-Xia ZhaoGuang-Wei JiaFan YangChuan-Zhou ZhangBing HanJian-Hua DaiYue-Qin HanBo-Hao TangXin-Mei YangHai-Yan ShiYue ZhouZhong-Guo SuiJian-Zhong ChenJohannes N van den AnkerWei Zhao

Published in: British journal of clinical pharmacology (2021)

The AUC of PEG-rhG-CSF (100 mcg/kg, 3 mg maximum dose) in paediatric patients with acute leukaemia were similar to those of PEG-rhG-CSF (100 mcg/kg) in children with sarcoma. PEG-rhG-CSF is safe, representing an important therapeutic option for chemotherapy-induced neutropenia in paediatric patients with acute leukaemia.

Keyphrases

recombinant human
chemotherapy induced
drug delivery
intensive care unit
emergency department
young adults
cerebrospinal fluid